What is the share price of Max Healthcare Institute Ltd (MAXHEALTH) today?
The share price of MAXHEALTH as on 19th June 2026 is ₹1094.75. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on Max Healthcare Institute Ltd (MAXHEALTH) share?
The past returns of Max Healthcare Institute Ltd (MAXHEALTH) share are- Past 1 week: 7.54%
- Past 1 month: 3.12%
- Past 3 months: 14.86%
- Past 6 months: 1.76%
- Past 1 year: -5.87%
- Past 3 years: 81.96%
- Past 5 years: 344.30%
What are the peers or stocks similar to Max Healthcare Institute Ltd (MAXHEALTH)?
The peers or stocks similar to Max Healthcare Institute Ltd (MAXHEALTH) include:What is the dividend yield % of Max Healthcare Institute Ltd (MAXHEALTH) share?
The current dividend yield of Max Healthcare Institute Ltd (MAXHEALTH) is 0.18.What is the market cap of Max Healthcare Institute Ltd (MAXHEALTH) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Max Healthcare Institute Ltd (MAXHEALTH) is ₹106545.86 Cr as of 19th June 2026.What is the 52 week high and low of Max Healthcare Institute Ltd (MAXHEALTH) share?
The 52-week high of Max Healthcare Institute Ltd (MAXHEALTH) is ₹1314.30 and the 52-week low is ₹903.What is the PE and PB ratio of Max Healthcare Institute Ltd (MAXHEALTH) stock?
The P/E (price-to-earnings) ratio of Max Healthcare Institute Ltd (MAXHEALTH) is 73.87. The P/B (price-to-book) ratio is 11.36.Which sector does Max Healthcare Institute Ltd (MAXHEALTH) belong to?
Max Healthcare Institute Ltd (MAXHEALTH) belongs to the Health Care sector & Hospitals & Diagnostic Centres sub-sector.How to buy Max Healthcare Institute Ltd (MAXHEALTH) shares?
You can directly buy Max Healthcare Institute Ltd (MAXHEALTH) shares on Tickertape. Simply sign up, connect your demat account and place your order.
Max Healthcare Institute Ltd
MAXHEALTH Share Price
NSEMAXHEALTH Stock Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is underpriced but is in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
MAXHEALTH Performance & Key Metrics
MAXHEALTH Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 73.87 | 11.36 | 0.18% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 41.31 | 6.17 | 0.56% |
from 23 analysts
Price Upside
Earnings Growth
Rev. Growth
MAXHEALTH Company Profile
Max Healthcare is provider of home health care services including Patient Care, Healthcare Services, and Hospitals.
MAXHEALTH Sentiment Analysis
MAXHEALTH Sentiment Analysis
MAXHEALTH Stock Summary · May 2026
Management framed the quarter as one of constructive operational momentum driven by phased capacity rollouts and disciplined commissioning, underpinned by FY26 network gross revenue of INR 10,538 crore and operating EBITDA of INR 2,638 crore (26.2% margin). They emphasized rapid brownfield activation and staged greenfield builds—more than 20% additional brownfield capacity across Mohali, Nanavati and Max Smart to be operationalized in the next 2–3 months, roughly 100 brownfield beds already EBITDA‑positive, a 500‑bed Gurugram project with an initial ~200 beds targeted for year‑end, and a Board‑approved INR 1,400 crore, 700‑bed Lucknow program on a multi‑year phased timeline—while stressing beds will only be opened where demand exists and clinical/non‑clinical staff have been onboarded to capture operating leverage. Management also acknowledged tension from a CGHS chemotherapy pricing change and drug withdrawals that trimmed oncology OBDs ~5–6% and lowered oncology’s inpatient share to ~21%, and a temporary 9% ALOS rise that reduced ARPOB; they quantified a net CGHS benefit of INR 140 crore (INR 100–110 crore realized, ~INR 30–40 crore outstanding) with no definitive reversal timeline. Near term, additional brownfield beds will be activated over coming quarters, Gurugram commissioning is moved to year‑end after a two‑month delay, and cash generation and lower net debt (INR 1,908 crore) are being used to fund expansion while margins absorb short‑term lumpiness.
MAXHEALTH Stock Growth Drivers
MAXHEALTH Stock Growth Drivers
5Accelerated capacity expansion and faster project execution
The company is materially increasing bed capacity through both brownfield and greenfield projects and demonstrating
Strong financial performance and robust cash generation with deleveraging
Financial results show consistent top‑line and margin strength alongside meaningful cash generation and balance‑sheet improvement.
MAXHEALTH Stock Challenges
MAXHEALTH Stock Challenges
5Oncology drug pricing change and chemotherapy discontinuations driving material revenue and margin hit
A sectoral pricing shift and related institutional MoU conditionalities forced hospitals to supply certain chemotherapy
Operational and regulatory disruptions causing project delays and execution risk
Several development projects have experienced multi‑month slippages and episodic stoppages driven by non‑routine operational and
MAXHEALTH Forecast
MAXHEALTH Forecasts
Price
Revenue
Earnings
MAXHEALTH Share Price Forecast
MAXHEALTH Share Price Forecast
All values in ₹
All values in ₹
MAXHEALTH Company Revenue Forecast
MAXHEALTH Company Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
MAXHEALTH Stock EPS (Earnings Per Share) Forecast
MAXHEALTH Stock EPS (Earnings Per Share) Forecast
All values in ₹
All values in ₹
MAXHEALTH
MAXHEALTH
Income
Balance Sheet
Cash Flow
MAXHEALTH Income Statement
MAXHEALTH Income Statement
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 1,380.99 | 1,468.15 | 1,577.63 | 1,748.30 | 1,901.61 | 1,956.66 | 2,064.08 | 2,168.37 | 2,112.90 | 2,190.72 | ||||||||||
| Operating & Other expenses | 949.11 | 1,041.37 | 1,155.54 | 1,256.92 | 1,442.81 | 1,398.12 | 1,504.66 | 1,560.32 | 1,577.42 | 1,536.46 | ||||||||||
| EBITDA | 431.88 | 426.78 | 422.09 | 491.38 | 458.80 | 558.54 | 559.42 | 608.05 | 535.48 | 654.26 | ||||||||||
| Depreciation/Amortization | 60.96 | 70.32 | 76.90 | 84.15 | 97.54 | 100.83 | 104.14 | 108.10 | 111.27 | 123.02 | ||||||||||
| PBIT | 370.92 | 356.46 | 345.19 | 407.23 | 361.26 | 457.71 | 455.28 | 499.95 | 424.21 | 531.24 | ||||||||||
| Interest & Other Items | 11.24 | 20.73 | 23.88 | 33.54 | 52.39 | 55.21 | 54.85 | 53.92 | 59.67 | 66.66 | ||||||||||
| PBT | 359.68 | 335.73 | 321.31 | 373.69 | 308.87 | 402.50 | 400.43 | 446.03 | 364.54 | 464.58 | ||||||||||
| Taxes & Other Items | 70.34 | 84.19 | 85.04 | 91.88 | 70.07 | 83.50 | 92.46 | -45.27 | 63.62 | 122.36 | ||||||||||
| Net Income | 289.34 | 251.54 | 236.27 | 281.81 | 238.80 | 319.00 | 307.97 | 491.30 | 300.92 | 342.22 | ||||||||||
| EPS | 2.98 | 2.59 | 2.43 | 2.90 | 2.46 | 3.28 | 3.17 | 5.05 | 3.10 | 3.52 |
MAXHEALTH Company Updates
Investor Presentation
MAXHEALTH Stock Peers
MAXHEALTH Past Performance & Peer Comparison
MAXHEALTH Past Performance & Peer Comparison
Health CareHospitals & Diagnostic Centres
Valuation
Technical
Forecast
| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Max Healthcare Institute Ltd | 73.87 | 11.36 | 0.18% |
| Apollo Hospitals Enterprise Ltd | 62.87 | 11.00 | 0.24% |
| Fortis Healthcare Ltd | 69.78 | 7.93 | 0.10% |
| Aster DM Healthcare Ltd | 107.79 | 11.46 | 0.36% |
MAXHEALTH Stock Price Comparison
Compare MAXHEALTH with any stock or ETFMAXHEALTH Holdings
MAXHEALTH Shareholdings
MAXHEALTH Promoter Holdings Trend
MAXHEALTH Promoter Holdings Trend
In last 6 months, promoter holding in the company has almost stayed constant
Pledged promoter holdings is insignificant
MAXHEALTH Institutional Holdings Trend
MAXHEALTH Institutional Holdings Trend
In last 3 months, retail holding in the company has almost stayed constant
In last 3 months, foreign institutional holding of the company has decreased by 5.17%
MAXHEALTH Shareholding Pattern
MAXHEALTH Shareholding Pattern
MAXHEALTH Shareholding History
MAXHEALTH Shareholding History
Mutual Funds Invested in MAXHEALTH
Mutual Funds Invested in MAXHEALTH
No mutual funds holding trends are available
Top 5 Mutual Funds holding Max Healthcare Institute Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 1.3263% | Percentage of the fund’s portfolio invested in the stock 1.38% | Change in the portfolio weight of the stock over the last 3 months 0.80% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 23/78 (+12) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.8441% | Percentage of the fund’s portfolio invested in the stock 2.46% | Change in the portfolio weight of the stock over the last 3 months 0.76% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 22/33 (-1) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6316% | Percentage of the fund’s portfolio invested in the stock 0.80% | Change in the portfolio weight of the stock over the last 3 months -0.12% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 25/138 (0) |
Compare 3-month MF holding change on Screener
smallcases containing MAXHEALTH stock
smallcases containing MAXHEALTH stock
Looks like this stock is not in any smallcase yet.
MAXHEALTH Events
MAXHEALTH Events
MAXHEALTH Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
MAXHEALTH Dividend Trend
No dividend trend available
MAXHEALTH Upcoming Dividends
MAXHEALTH Upcoming Dividends
No upcoming dividends are available
MAXHEALTH Past Dividends
MAXHEALTH Past Dividends
Cash Dividend
Ex DateEx DateJul 4, 2025
Dividend/Share
₹1.50
Ex DateEx Date
Jul 4, 2025
Cash Dividend
Ex DateEx DateAug 23, 2024
Dividend/Share
₹1.50
Ex DateEx Date
Aug 23, 2024
Cash Dividend
Ex DateEx DateSep 8, 2023
Dividend/Share
₹1.00
Ex DateEx Date
Sep 8, 2023
MAXHEALTH Stock News & Opinions
MAXHEALTH Stock News & Opinions
Max Healthcare Institute announced that the Board of Directors of the Company at its meeting held on 21 May 2026, inter alia, have recommended the final dividend of Rs 2 per equity Share (i.e. 20%) , subject to the approval of the shareholders.
Net profit of Max Healthcare Institute rose 7.28% to Rs 342.22 crore in the quarter ended March 2026 as against Rs 319.00 crore during the previous quarter ended March 2025. Sales rose 12.21% to Rs 2142.89 crore in the quarter ended March 2026 as against Rs 1909.74 crore during the previous quarter ended March 2025. For the full year,net profit rose 34.07% to Rs 1442.41 crore in the year ended March 2026 as against Rs 1075.88 crore during the previous year ended March 2025. Sales rose 19.14% to Rs 8373.45 crore in the year ended March 2026 as against Rs 7028.46 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales2142.891909.74 12 8373.457028.46 19 OPM %28.3026.79 -26.7926.30 - PBDT587.60503.33 17 2170.351839.42 18 PBT464.58402.50 15 1723.821480.00 16 NP342.22319.00 7 1442.411075.88 34 Powered by Capital Market - Live
Revenue from operations rose 12.20% YoY to Rs 2,142.89 crore during the quarter. The company's network gross revenue stood at Rs 2,664 crore, registering a 10% YoY growth, primarily driven by higher occupied bed days (OBDs). International patient revenue increased 12% YoY to Rs 227 crore and contributed around 9% of hospital revenue. Network operating EBITDA came in at Rs 682 crore, up 8% YoY. EBITDA margin for the network stood at 26.8% compared with 27.2% in Q4 FY25 and 26.1% in Q3 FY26. The company said clinician costs increased nearly 230 basis points YoY and 120 basis points sequentially due to aggressive hiring of clinical talent to support future growth and ongoing capacity expansions. Overall EBITDA per bed stood at Rs 73.4 lakh compared with Rs 73.9 lakh in Q4 FY25 and Rs 71.3 lakh in Q3 FY26. Max Lab, the company's non-captive pathology business, reported revenue of Rs 52 crore during the quarter, reflecting growth of 14% YoY and 11% QoQ. The pathology network now operates across more than 60 cities and offers over 2,700 tests. Max@Home reported gross revenue of Rs 73 crore, up 30% YoY and 8% QoQ, driven by growth in physiotherapy, rehabilitation, nursing care, sample collection, and medicine delivery services. Network PAT stood at Rs 387 crore, compared with Rs 376 crore in Q4 FY25, registering growth of 3% YoY and 12% sequentially. Free cash flow from operations rose to Rs 581 crore in Q4 FY26 from Rs 422 crore in the year-ago quarter. During the quarter, the company deployed Rs 328 crore towards ongoing expansion plans and new unit upgrades. Net debt at the end of March 2026 stood at Rs 1,908 crore compared with Rs 2,166 crore at the end of December 2025. The company said nearly 20% additional brownfield capacity has been commissioned over the last six months, with another 10% capacity addition expected from the upcoming Gurugram facility later this year. A 400-bed brownfield tower at Max Smart Super Speciality Hospital was commissioned in April 2026. Currently, 156 beds have been handed over to operations, with the remaining beds expected to be progressively handed over during the next quarter. Additionally, a 160-bed brownfield tower at MSSH, Mohali has been fully commissioned and operationalized. Similarly, 116 beds out of the planned 280-bed brownfield tower at Nanavati Max have been operationalized, with the balance beds expected to become operational over the next three months. Max Healthcare also completed the acquisition of a 58.28% controlling stake in Kalinga Hospital on 18 May 2026, making it a subsidiary of the company. Kalinga Hospital operates a 250-bed facility spread across a prime 10-acre land parcel in the heart of Bhubaneswar, Odisha. Meanwhile, the board approved an investment of around Rs 1,400 crore for the construction of a 712-bed greenfield hospital at Shaheed Path in Lucknow. The facility is expected to be commissioned in FY30. Abhay Soi, chairman and managing director, Max Healthcare Institute, said, 'We are pleased to announce the phased commissioning and ramp-up of brownfield expansions across Mohali, Mumbai and Delhi, representing approximately 20% capacity addition. We also look forward to augmenting our capacity by another ~10% with the commissioning of the greenfield Gurgaon facility by the end of the year. We are also happy that the network has delivered its 22nd consecutive quarter of year-on-year growth, with revenue increasing by 10% and operating EBITDA grew by 8%. Further, we have completed the acquisition of a controlling stake in Kalinga Hospital, Bhubaneswar. The team has already begun integration and is working towards achieving significant operational upside. In parallel, work has commenced on the upgradation and expansion of the hospital, enabling us to extend high-quality healthcare services in a fast-growing region.' further, the company's board has recommended a final dividend of Rs 2 per equity share of face value Rs 10 each for FY26, subject to shareholders' approval at the forthcoming annual general meeting (AGM). If approved, the dividend will be paid or dispatched within 30 days from the conclusion of the AGM. Max Healthcare Institute (Max Healthcare) is one of India's largest healthcare organisations. The company operates 21 healthcare facilities (nearly 6,000 beds) with a significant presence in North India. In addition to the hospitals, Max Healthcare operates homecare and pathology businesses under brand names Max@Home and Max Lab, respectively. The scrip had added 1.42% to end at Rs 1091.55 on the BSE. Powered by Capital Market - Live
Max Healthcare Institute will hold a meeting of the Board of Directors of the Company on 21 May 2026.
Max Healthcare Institute has allotted 51,287 equity shares under ESOS on 01 May 2026. With this allotment, the paid up equity share capital has increased to 97,32,43,789 equity shares of Rs 10 each.
Under the agreement, MHIL shall acquire 58.4% stake in KHL at an equity value of Rs 300 crore. The 250 bed NABH accredited hospital is built on a 10-acre land parcel at Maitri Vihar, Bhubaneswar, a prime location in the heart of the city. Spread over 2.60 lakh square feet, the hospital provides multidisciplinary care across major specialties, including neurology, cardiology, orthopaedics, gastroenterology, renal sciences and oncology; backed by diagnostics and equipped with a 128-slice CT scanner, 1.5T MRI, and cath lab, etc. Bhubaneswar has a well-developed healthcare eco-system with large footprint of public, private hospitals and multiple medical colleges, positioning the city as a preferred healthcare provider for patients from across Odisha and neighbouring states of West Bengal, Jharkhand and Chhattisgarh. This acquisition will strengthen MHIL's network and expand its footprint in Eastern India. Abhay Soi, chairman and managing director, Max Healthcare Institute, said: 'Happy to announce our foray into Bhubaneswar, an extremely attractive market, through the acquisition of a very well located and reputable hospital with significant operational upside and brownfield potential.' Max Healthcare Institute is one of India's largest healthcare organizations. The company operates 20 healthcare facilities, with a significant presence in North India. In addition to the hospitals, Max Healthcare operates homecare and pathology businesses under brand names Max@Home and Max Lab, respectively. The company's consolidated net profit rose 26.01% to Rs 300.92 crore on a 10.66% increase in revenue to Rs 2,067.52 crore in Q3 FY26 over Q3 FY25.
The board of Max Healthcare Institute at its meeting held on 08 April 2026 has approved to enter into share purchase agreement (SPA) for acquisition of controlling stake (~58.39%) in Kalinga Hospital (KHL), which operates a 250 bedded Multi-Specialty Hospital by the name of 'Kalinga Hospital' in Bhubaneswar, Orissa. Further, the board has approved to provide loans up to Rs 100 crore to KHL towards cost of construction, renovation, upgradation, equipment etc. The Board has also approved issuance of corporate guarantee to Bank/ Financial Institution for re-financing of external commercial borrowings of existing promoter of KHL of $5 Mn (along with interest due thereon). Also, the board has approved the senior secured term loan of amount up to Rs 300 crore in the form of external commercial borrowings for financing the acquisition.
Max Healthcare Institute has allotted 57,461 equity shares under ESOP on 01 April 2026. With this allotment, the paid up equity share capital has increased to Rs 973,19,25,020 comprising of 97,31,92,502 equity shares of Rs 10 each.
Max Healthcare Institute has allotted 42,266 equity shares under ESOS on 17 March 2026. With this allotment, the paid up equity share capital has increased to 97,31,35,041 equity shares of Rs 10 each. Powered by Capital Market - Live
Net profit of Max Healthcare Institute rose 26.01% to Rs 300.92 crore in the quarter ended December 2025 as against Rs 238.80 crore during the previous quarter ended December 2024. Sales rose 10.66% to Rs 2067.52 crore in the quarter ended December 2025 as against Rs 1868.31 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales2067.521868.31 11 OPM %26.0426.72 - PBDT524.05480.04 9 PBT412.78382.50 8 NP300.92238.80 26 Powered by Capital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 45.36%, vs industry avg of 13.41%
Over the last 5 years, market share increased from 2.66% to 8.72%
Over the last 5 years, net income has grown at a yearly rate of 78.73%, vs industry avg of 42.52%